Immunome is a clinical-stage biotechnology company developing antibody-based therapeutics. Its programs focus on oncology and related disease areas, advancing candidates discovered or in-licensed through antibody discovery platforms. The company has little product revenue and depends on R&D progress, partnerships and capital markets typical of development-stage biotech. Its audience is the biopharma and clinical research community rather than commercial drug buyers today.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 4 | — | -43.4 | — |
| Q3 2025 | 0 | — | -57.5 | — |
| Q4 2025 | 0 | — | -69.9 | — |
| Q1 2026 | 0 | — | -53.8 | — |
| Q2 2026 | 0 | -100% | -73.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Trump Media & Technology Group Corp. (DJT), nLIGHT, Inc. (LASR), eToro Group Ltd. (ETOR), SolarEdge Technologies, Inc. (SEDG), Plug Power Inc. (PLUG), Patria Investments Limited (PAX)